Clinical trials: Adenocarcinoma of the Prostate
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
A Study to Evaluate the Performance of Confocal Microscopy to Detect Positive Margins During Radical Prostatectomy
The goal of this study is to find out whether a new method called "LaserSAFE" can accurately detect cancer at the edge of the prostate (called a positive margin) during prostate surgery.
- Trial name
- LaserSAFE (NCT07541911)
- Testing
- LaserSAFE
- Where
- United Kingdom
- Volunteers
- 693 people
- Sponsor
- University College, London
Prostate Cancer Adenocarcinoma
Spatial Multi-Omics of Perineural Invasion Microenvironment and Prognosis in Prostate Cancer
Prostate cancer is a common malignancy in men, with substantial prognostic heterogeneity that calls for improved risk stratification at the tissue microenvironment level.
- Trial name
- NCT07818395
- Testing
- Multi-omics profiling
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Anhui Medical University
Prostate Cancer
Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer
RATIONALE: Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00060437
- Testing
- perifosine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Male Erectile Disorder, Prostate Adenocarcinoma
Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer
This phase II trial studies how well pentoxifylline, atorvastatin, and vitamin E (PAVE) work in treating patients with erectile dysfunction after radiation therapy for prostate cancer. Atorvastatin may reduce high cholesterol.
- Conditions
- Male Erectile Disorder, Prostate Adenocarcinoma, Erectile Dysfunction, CTCAE, Impotence
- Trial name
- NCT03830164
- Testing
- Atorvastatin, Pentoxifylline, Vitamin E Compound
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05691465
- Testing
- Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE
- Where
- 13 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Adenocarcinoma
Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid
The present randomized, open, multicentric Phase II trial, in parallel groups with two arms of treatment, compares the treatment A, moderate hypofractionated radiotherapy of 62Gy, to treatment B, stereotactic irradiation of 37.5…
- Trial name
- RPAH2 (NCT02361515)
- Testing
- Moderate hypofractionated radiotherapy, Stereotactic radiotherapy
- Where
- 7 sites in France
- Volunteers
- 96 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer, Prostate Adenocarcinoma
Clinical Trial of Green Tea Catechins in Men on Active Surveillance
This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation of whole Green Tea Catechin, (Sunphenon® 90D)…
- Trial name
- NCT04300855
- Testing
- Sunphenon
- Where
- 2 sites in United States
- Volunteers
- 115 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Vitamin D and soy extract may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment.
- Trial name
- NCT00499408
- Testing
- Vitamin D, soy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized…
- Trial name
- NCT01492972
- Testing
- Radiation, Androgen Suppression Therapy
- Where
- 4 sites in United States
- Volunteers
- 192 people
- Sponsor
- Proton Collaborative Group
Prostate Cancer, BRCA1 Mutation
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or…
- Conditions
- Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma
- Trial name
- NePtune (NCT05498272)
- Testing
- Olaparib, LHRH agonist
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Rana McKay, MD
Prostate Adenocarcinoma
Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device as a neo-adjuvant therapy in men with prostate cancer
- Trial name
- NCT04543903
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- 3 sites in Israel
- Volunteers
- 1 people
- Sponsor
- Alpha Tau Medical LTD.
Prostate Cancer
Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with G-CSF may make tumor cells more sensitive to the chemotherapy drug and may kill…
- Trial name
- NCT00003183
- Testing
- filgrastim, mitoxantrone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Hope Cancer Institute, Inc.
Prostate Adenocarcinoma, Radiotherapy; Complications
Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy
Feasibility trial of twice high dose radiotherapy using Tomotherapy in patients with organ confined Prostate Cancer histologically proven.
- Conditions
- Prostate Adenocarcinoma, Radiotherapy; Complications, Tomotherapy
- Trial name
- THRIP (NCT03553212)
- Testing
- tomotherapy
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate Adenocarcinoma
Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer
The present study is a phase III randomized and multicentric trial evaluating the potential additional impact effect of two years adjuvant androgen deprivation when combined with neoadjuvant (4 months) and high-dose (76 Gy)…
- Trial name
- AADLPC (NCT02175212)
- Testing
- Short term androgen deprivation, Long term androgen deprivation
- Where
- Spain
- Volunteers
- 362 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Prostate Adenocarcinoma
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression.
- Trial name
- RAD 2003 (NCT04743934)
- Testing
- Flibanserin 100 MG, Androgen deprivation therapy
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Andrew McDonald
Prostate Cancer
Image Guided Radiation Therapy For Prostate Cancer
During the 7 to 8 weeks of conformal radiotherapy for prostate carcinoma, the prostate has an intra-pelvic motion which is not detectable by the conventional portal imaging.
- Trial name
- NCT00433706
- Testing
- Control position by 3DOBI before the fraction, Standard imaging
- Where
- France
- Volunteers
- 470 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
To Evaluate the Rate of Digestive and Urinary Toxicity
Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk
The standard treatment of high-risk prostatic adenocarcinoma is based on pelvic-prostatic external radiotherapy combined with concomitant and adjunctive hormone therapy for a total of 3 years.
- Trial name
- SHORT (NCT03417336)
- Testing
- prostatic boost in brachytherapy with high dose rate (HDR)
- Where
- 2 sites in France
- Volunteers
- 90 people
- Sponsor
- Centre Georges Francois Leclerc
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Prostate Cancer
Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens.
- Trial name
- NCT00309894
- Testing
- sargramostim, ketoconazole, therapeutic hydrocortisone
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of California, San Francisco
Cancer Survivor, Obesity
Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer
This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors.
- Conditions
- Cancer Survivor, Obesity, Overweight, Prostate Adenocarcinoma
- Trial name
- NCT03880422
- Testing
- Dietary Intervention, Educational Intervention, Exercise Intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Roswell Park Cancer Institute